Compare SaaS Products

Proteins power everything from the cells in your body to creating materials you rely on every day, but until now, we’ve been forced to discover their functions by trial and error. Designing a new therapeutic can take decades and billions of dollars, and even our best industrial catalysts work at a snail’s pace compared to their theoretical optimums. Anthrogen is changing that. By training massive AI foundation models on protein sequences and structures, we’ve unlocked the ability to generate, on demand, completely novel molecular machines with atomic-level precision. Simply describe the function you need, and our platform imagines the peptide or protein that will deliver it. We're building models to speed up billions of years of evolution into the span of an afternoon's worth of compute. The result? New-to-nature therapies, ultra-efficient catalysts for sustainable manufacturing, and a whole new frontier of molecular innovation, designed as precisely as any cutting-edge aircraft or microchip.

Argon AI is a platform where biopharma and life sciences professionals can execute complex and data driven workflows using natural language. We help professionals get thorough answers to questions about clinical trials, existing treatments, healthcare landscape, and the competitive market in minutes rather than months. Prior to starting Argon, Samy was responsible for Flatiron Health’s (Roche) first data analytics project which eventually led to the start of the Flatiron Services business unit. There, he saw first-hand the heavily manual process that biopharma companies struggle through to get the insights they need to drive forward their drug development programs. He also helped close over $6M+ in ARR and is an expert in enterprise pharma sales. Cyrus previously led engineering teams and built 0 to 1 across pre-seed and unicorn startups, managed mission-critical trade generation systems at Bridgewater, and held AI advisory roles at various startups. Cyrus has a duel degree in EE and CS from USC. Breakthroughs in AI present an opportunity to reinvent biopharma and life science workflows to reduce the time and cost of bringing treatments to patients where delays in bringing a drug to market can cost a pharma company $3M / day.